Abstract
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. Liver transplant is considered the gold standard for curative therapy for HCC when patients are not candidates for surgical resection or ablation. Because a subset of patients with HCC have a survival rate with liver transplantation that is comparable to that of cirrhotic patients without tumors, the organ allocation system allows for increased priority for transplant in potential recipients within the Milan criteria. With the recent change in the Model for End-Stage Liver Disease exception point allocation, patients with HCC will now need to wait at least 6 months before being awarded extra points. This extension leads to increased time on the transplant waiting list and underscores the importance of locoregional therapy to contain the tumor burden. Fortunately, there has been significant progress in therapy for HCC in the past few decades, namely due to advances in interventional radiology, radiotherapy, and expanded surgical and transplant criteria. Recent advances in immunotherapy also provide promising options for patients who are not candidates for other therapies. This article highlights the major therapeutic options for HCC, including surgical resection, liver transplant, thermal and nonthermal ablation, chemoembolization, radiotherapy, and systemic chemotherapy, as well as discusses the evidence supporting these approaches.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 398-410 |
| Number of pages | 13 |
| Journal | Gastroenterology and Hepatology |
| Volume | 13 |
| Issue number | 7 |
| State | Published - Jul 1 2017 |
Fingerprint
Keywords
- Hepatocellular carcinoma
- Immunotherapy
- Interventional oncology
- Treatment
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
Cite this
Advances and future directions in the treatment of hepatocellular carcinoma. / Gosalia, Ashil J.; Martin, Paul; Jones, Patricia D.
In: Gastroenterology and Hepatology, Vol. 13, No. 7, 01.07.2017, p. 398-410.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Advances and future directions in the treatment of hepatocellular carcinoma
AU - Gosalia, Ashil J.
AU - Martin, Paul
AU - Jones, Patricia D.
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. Liver transplant is considered the gold standard for curative therapy for HCC when patients are not candidates for surgical resection or ablation. Because a subset of patients with HCC have a survival rate with liver transplantation that is comparable to that of cirrhotic patients without tumors, the organ allocation system allows for increased priority for transplant in potential recipients within the Milan criteria. With the recent change in the Model for End-Stage Liver Disease exception point allocation, patients with HCC will now need to wait at least 6 months before being awarded extra points. This extension leads to increased time on the transplant waiting list and underscores the importance of locoregional therapy to contain the tumor burden. Fortunately, there has been significant progress in therapy for HCC in the past few decades, namely due to advances in interventional radiology, radiotherapy, and expanded surgical and transplant criteria. Recent advances in immunotherapy also provide promising options for patients who are not candidates for other therapies. This article highlights the major therapeutic options for HCC, including surgical resection, liver transplant, thermal and nonthermal ablation, chemoembolization, radiotherapy, and systemic chemotherapy, as well as discusses the evidence supporting these approaches.
AB - Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. Liver transplant is considered the gold standard for curative therapy for HCC when patients are not candidates for surgical resection or ablation. Because a subset of patients with HCC have a survival rate with liver transplantation that is comparable to that of cirrhotic patients without tumors, the organ allocation system allows for increased priority for transplant in potential recipients within the Milan criteria. With the recent change in the Model for End-Stage Liver Disease exception point allocation, patients with HCC will now need to wait at least 6 months before being awarded extra points. This extension leads to increased time on the transplant waiting list and underscores the importance of locoregional therapy to contain the tumor burden. Fortunately, there has been significant progress in therapy for HCC in the past few decades, namely due to advances in interventional radiology, radiotherapy, and expanded surgical and transplant criteria. Recent advances in immunotherapy also provide promising options for patients who are not candidates for other therapies. This article highlights the major therapeutic options for HCC, including surgical resection, liver transplant, thermal and nonthermal ablation, chemoembolization, radiotherapy, and systemic chemotherapy, as well as discusses the evidence supporting these approaches.
KW - Hepatocellular carcinoma
KW - Immunotherapy
KW - Interventional oncology
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=85026653093&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026653093&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:85026653093
VL - 13
SP - 398
EP - 410
JO - Gastroenterology and Hepatology
JF - Gastroenterology and Hepatology
SN - 1554-7914
IS - 7
ER -